18: Anticoagulant toxicity Flashcards

1
Q

what is the INR target for mechanical heart valves, aFib and VTE

A

mech valves = 2.0-3.5
AFIB and BTE - 2.0-3.0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is defined as minor bleeding

A

trivial bleed that resolves within 20 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is defined as a major bleed

A

bleeding into critical organ or a decline in HgB 20g/L (requires transfusions (1 pack of blood ~10g/L)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CBCs should be done _________ for those on anticoagulants

A

yearly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

which is more easily treated? bleeds or clots

A

bleeds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the most feared bleeding complication

A

intracranial bleed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

which 2 types of intracranial bleed is typically due to trauma in the elderly but prognosis is typically good

A

epidural or subdural hematoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

which of the following has worse prognosis
1. epidural hematoma
2. subdural hemoatoma
3. subarachnoid hemorrhage
4. intracerebral hemorrhage
5. 1+2
6. 3+4

A

6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

why are intracranial hemorrhages so dangerous

A

Fixed space (within skull), concern with initial volume and expansion of bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hemorrhages on anticoagulants have higher (3)

initial______
risk of _____
severity/ probability of ____

A

initial volume
risk of expansion
severity/ probability of death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DOACs reduce risk of aaICH by ________ compared to warfarin

A

30-70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

compared to warfarin, DOAC ICHs have (3)

______ volumes of blood
less severe ______/ more functional recovery
fewer ____s

A

smaller volumes of blood
less severe strokes/ more functional recovery
fewer deaths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the msot common extracranial bleed

A

GI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

in extracranial major bleeding from ACs
1. majority result in full recovery spontaneously
2. requires reversal or interruption of treatment
3. the most common area is the lungs (pneumothorax)
4. none of the above is true

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

DOACs ___________ compared to warfarin
1. decreases both ICH and GI bleeds
2. increases ICH and decreases GI bleed
3. decreases ICH and increases GI bleed
4. increases ICH and GI bleeds

A

3 (but increase in GI bleeds is not stat sig)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

T or F: high bleed risk score is not a reason to avoid anticoagulants

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

in ____, thrombotic and bleed rsk often rise in parallel

A

AF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what 6 things must you do for assessment of bleed

A

location
timing of blood loss
quantify and qualify blood loss
immediate mnagement
future management
impact of major bleed vs clotting event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

generally, what is a good time to restart anticoagulation tx

____ usually
_ week if cause of bleed identified and rectified
_____ wks if conservative approach

A

2wks usually
1 week if cause of bleed identified and rectified
2-8 wks if conservative approach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

observational data shows that restarting AC after GIB ____________________________

A

reduces risk of thrombosis and mortality and doesn’t increase risk of recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

observational data shows that restarting AC after ICH ___________________

A

decreases risk of ischemic events and mortality + no differences in major bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

critical INRs are defined as

23
Q

WHO requires labs to perform quality assurance testing between INR ________

A

1.5-4.5 only

24
Q

what are 4 general categories of factors that elevate the INR

______ in health
changes to ________
changes to ______
administration of_________

A

deteriorations in health
changes to medications
changes to lifestyle
administration of too much warfarin

25
what changes in lifestyle may affect INR
vit K intake alcohol consumption level of activity
26
induction/ inhibition of this CYP enzyme causes major changes to INR ___________. minor changes occur with ___ and __________
2C9 = major minor = 3A4, 1A2
27
IV vit K admin for warfarin reversal is used in ___________ and takes affect in _____________
life threatening situations 6-12hrs
28
oral vit K is used in ________ and takes effect in ______________
nonemergency situations 16-24hrs
29
what 2 routes of vit K should be avoided
IM and SQ
30
typical ER dose of IV vit K
10mg
31
in a pt with INR 4.5-10.0 guidelines suggest _______ routine use of vit K - can you "consider" vitK?
against routine use of vit K hold 1-2 warfarin doses and consider vit K PO 1-2.5mg and reassess INR
32
in a pt with INR >10, guidelines suggest
hold warfarin vit K PO 2-5mg and reassess INR
33
PCC reverses INR within
minutes
34
after a critical INR has been managed and the acute, reversible cause identified, what action should take place?
document INR <4 implement warfarin dosing similar to that prior to the cause occured
35
after a critical INR has been managed and the acute, non reversible cause identified but will continue, what action should take place?
document INR <4 empirically decrease warfarin dosing based on experience/ literature
36
after a critical INR has been managed and no identifiable reason has been found what action should take place?
document INR <4 depending on clot vs bleed risk, reduce maintenance dosing accordingly (typically ~10% decrease but individualize based on pt)
37
PCC is derived from ______ and administered by _________
human plasma IV infusion
38
PCC contains factors ___________ and protein ____________
factors 2, 7, 9, 10 C, S
39
PCC reduces INR within minutes but the effect is not sustained, _______ must also be administered to sustain reversal in INR
vit K (~10mg)
40
PCC indications (2)
Serious or life threatening bleeding Requires urgent (<6hrs) interventions with risk of bleeding
41
aPPC contains _____________ and is mostly used in ___________
activated factor 2a (i think it's atually 7a....) hemophilia patients
42
rank the DOACs based on renal elimination
dabig > edoxi > rivaroxi >apixa
43
which DOAC can be removed by dialysis
dabigatran
44
there may be an accumulation of DOACs if
overdose, acute renal failure, DDI (strong P-gp inhibitor for D and E, strong P-gp + 3A4 inhibition for R and A)
45
when would DOAC reversal be needed
major bleeding or urgent need for procedure acute ischemic stroke (and desire for thrombolysis- off label)
46
antifibrinolytisc MOA
inhibit fibrinolysis by preventing conversion of plasminogen to plasmin, plasmin then can’t act on fibrin to clot
47
T or F: antifibrinolytics are antidotes for DOACs and warfarin
F- doesn't make clots, only blocks their break down
48
what are 2 practiacl uses of antifibrinolytic agents
topical if dental/ nasal bleeding, oral if heavy menstruation or IV in operating room
49
dabigatraan antidote is __________, which is a _____________ that binds ________ to dabigatrain with 350x stronger affinity than thrombin
idarucizumab enginerred antibody fragment noncompetitively to dabigaatran
50
idarucizumaba is indicated for adult pts treated with dabigatran when
rapid reversal of anticoagulant effect is required for emergency surgery/ urgent procedures or life threatening or uncontrolled bleeding
51
what is the antidote for factor Xa inhibitors
andexanet alfa
52
andexanet alf is a _______________ that acts as _________ with high specificity for both oral and injectable Fxa inhibitors
modified recomb factor Xa competitive decoy to target and sequester
53
andexanet alfa is catalytically _____
inactive